AHA 2019 The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

AHA 2019 The ORION-10 data showed LDL-c lowering of over 50% with inclisiran, which inhibitors production of PCSK9 through RNA interference, with a safety profile similar to placebo.

Final results from the open-label OSLER-1 study on evolocumab show long-term reduction in LDL-C levels without attenuation of the LDL-lowering effect and consistent safety and tolerability profiles during 5-years.

Starting evolocumab treatment on top of high-intensity statin, in the hospital soon after ACS, safely and effectively lowers LDL-c to below guideline-recommended levels for almost all.

Topline results of ORION-9 and ORION-10 showed durable and potent efficacy and safety of twice-yearly injections of inclisiran in HeFH patients and participants with ASCVD, respectively.

ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

In the FOURIER trial, evolocumab reduced LDL-c by ~60% in patients with established CVD. Prof. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor.

Prof. Kastelein discusses new strategies to target PCSK9, including twice-a-year injections of inclisiran and a new developed oral PCSK9 inhibitor.

ESC 2019 Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.

Phase 3 ORION-11 results up to 18 months show efficacy of inclisiran, which prevents production of the PCSK9 protein, consistent with earlier studies and an at least as favorable safety profile.

In a large Danish contemporary general population study, low LDL-c due to PCSK9 genetic variation caused a lower CV mortality risk. Cancer and all-cause mortality were not altered by the gene variants.